当前位置: 希尼尔首页 > 双语新闻



中国将降低癌症药物及进口药物价格(中英双语)

青岛希尼尔翻译咨询有限公司(www.sinosenior.com)整理发布  2016-03-10

  

青岛希尼尔翻译公司(www.sinosenior.com)2016年3月10日了解到:SHANGHAI - China has signalled its intent to cut prices of medicines used to treat serious diseases such as cancer, part of a wider drive to reduce the cost of healthcare for patients in the world’s second-biggest economy.

(上海)中国已经表明其将降低治疗如癌症之类的严重疾病的药物。这是世界第二大经济体加大减轻患者医疗经济负担的部分计划。

The National Health and Family Planning Commission is negotiating a pilot programme with drug firms to lower the price of five drugs, the official Xinhua news agency reported on Wednesday, citing Li Bin, the head of the commission.

周三,新华社引用国家卫生和计划生育委员会主任李斌的话称,卫计委正和药企商议一个降低五种药物价格的试验计划。

The high cost of healthcare is a major point of contention in China, where low levels of state health insurance coverage means patients and their families often burn through savings to buy drugs to treat chronic disease.

天价医疗费用是中国的主要社会矛盾之一。较低的国家健康保险意味着患者和他们的家人需要砸锅卖铁来购买药物以治疗慢性疾病。

"We are taking measures to satisfy people’s need for drugs, especially to resolve issues of high-priced patented drugs and patients unable to afford medicines," Li said on the sidelines of the National People’s Congress (NPC) in Beijing.

李斌在全国人大非正式会议上表示:“我们正在采取措施来满足人们的药物需求,特别是针对一些高价的专利药以及患者无力购买的药物。”

China’s drive to lower the price of drugs is one of the main challenges facing drug firms in the world’s second-largest medicine market, where growth has slowed markedly over the past couple of years. Beijing is also supporting domestic firms to take a bigger share of the market.

中国降低药物价格的意图是药企目前面临的主要挑战。该世界第二大药物市场的增长率在过去几年内显著下滑。中国政府同样支持本土公司在市场中占据更大份额。

Li said the pilot scheme would seek to reduce the price of the five drugs by over half, adding the drugs were currently expensive because they were patented or imported. She did not name the drugs or the companies which made them.

李斌说,该试验计划将争取将五种药物的价格降低一半,并补充说这些药物目前价格昂贵是因为它们是专利药物或者是进口药物。她并未点出这些药物和制药公司的名字。

China’s cancer drug market is led by Swiss firm Roche Holding AG (ROG.S), followed by China’s Qilu Pharmaceutical, Jiangsu Hengrui Medicine , Jilin Aodong Pharmaceutical Group and Britain’s AstraZeneca PLC (AZN.L), Deutsche Bank said in a 2015 report.

德意志银行在2015年的一份报告中称,瑞士公司罗氏制药在中国的癌症药物市场占据了最大份额,中国齐鲁药事、江苏恒瑞医药、吉林敖东以及英国阿斯利康公司紧随其后。来源:爱语吧


注:部分新闻来源于网路,如有涉及版权,请及时通知我们,我们将尽快删除。

---------------------------------------------------------------------------------------------------------------------------------------------------------------

青岛翻译公司  驾照翻译  学历认证翻译  翻译区域